Amgen Inc. (AMGN)
- Previous Close
262.75 - Open
264.21 - Bid 267.96 x 100
- Ask 268.51 x 100
- Day's Range
260.68 - 268.33 - 52 Week Range
211.71 - 329.72 - Volume
1,585,407 - Avg. Volume
2,926,216 - Market Cap (intraday)
143.797B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
21.48 - EPS (TTM)
12.48 - Earnings Date May 2, 2024
- Forward Dividend & Yield 9.00 (3.43%)
- Ex-Dividend Date May 16, 2024
- 1y Target Est
306.20
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
www.amgen.com26,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AMGN
Performance Overview: AMGN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMGN
Valuation Measures
Market Cap
140.93B
Enterprise Value
194.60B
Trailing P/E
21.04
Forward P/E
13.62
PEG Ratio (5yr expected)
2.36
Price/Sales (ttm)
5.01
Price/Book (mrq)
22.61
Enterprise Value/Revenue
6.90
Enterprise Value/EBITDA
13.15
Financial Highlights
Profitability and Income Statement
Profit Margin
23.83%
Return on Assets (ttm)
6.29%
Return on Equity (ttm)
135.79%
Revenue (ttm)
28.19B
Net Income Avi to Common (ttm)
6.72B
Diluted EPS (ttm)
12.48
Balance Sheet and Cash Flow
Total Cash (mrq)
10.94B
Total Debt/Equity (mrq)
1,049.79%
Levered Free Cash Flow (ttm)
3.12B
Research Analysis: AMGN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: AMGN
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Analyst Report: AMGEN Inc.
Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Prolia, Enbrel, Otezla, Xgeva, Tepezza, Repatha, Nplate, Kyprolis, Aranesp, and Evenity. The shares are a component of the S&P 500.
RatingBullishPrice TargetMarket Digest: AMGN, IQV
Almost two months in 2024, and stocks have seen more recovery highs and the major indices have seen more all-time highs. The S&P 500 (SPX) rose 1.7% in the week ended February 23, the S&P 100 popped 1.9%, the Nasdaq and the Nasdaq 100 added 1.4%, the S&P 400 tacked on 1%, and the Russell 2000 lost 0.9%. For the SPX, the '100,' and both Nasdaq indices, the week was the fifteenth of 17 on the upside; it is 14 of 17 for the '400.' During the 17 weeks, the SPX has gained 23.6%, while both Nasdaq indices are up over 26%. Those are great returns for a full year!
Analyst Report: Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingNeutralPrice Target